INHIBITION OF CELLULAR-TRANSPORT SYSTEMS BY ALKYL PHOSPHOLIPID ANALOGS IN HL-60 HUMAN LEUKEMIA-CELLS

被引:39
作者
HOFFMAN, DR
THOMAS, VL
SNYDER, F
机构
[1] UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75230
[2] OAK RIDGE ASSOCIATED UNIV,OAK RIDGE,TN 37830
关键词
ALKYL PHOSPHOLIPID; ANTINEOPLASTIC AGENT; NUTRIENT TRANSPORT SYSTEM;
D O I
10.1016/0005-2760(92)90203-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Specific non-metabolizable alkyl-phospholipids selectively kill neoplastic cells, yet normal and more differentiated cells are relatively resistant. Although these highly selective anticancer lipids appear to target the cell membrane, their mechanism of cytotoxic action remains to be defined. We report here that treatment of 'sensitive' HL-60 leukemia cells with one of the most potent lipid agents, 1-alkyl-2-methoxy-glycero-3-phosphocholine, inhibits the cellular transport of multiple essential nutrients including choline, amino acids, fatty acids, and the non-metabolizable carbohydrate, 2-deoxy-D-glucose. Minimal inhibitory responses of the varied transport systems were noted in HL-60 cells treated with the less potent, 2-lyso analog, and in 'resistant' K562 leukemia cells, treated with the 2-methoxy lipid. Although both the 2-methoxy lipid and 12-tetradacanoylphorbol 13-acetate induce differentiation in HL-60 cells, significant differences in the interactions of these lipids on cellular choline transport were found. Based on these results, we conclude that multiple nutrient deprivation induced by the detergent-like action of the methoxy-containing alkyl phospholipid results in the selective destruction of neoplastic cells that are sensitive to this membrane-targeted antitumor agent.
引用
收藏
页码:74 / 80
页数:7
相关论文
共 39 条
[1]  
ANDREESEN R, 1978, CANCER RES, V38, P3894
[2]   TUMOR CYTO-TOXICITY OF HUMAN MACROPHAGES AFTER INCUBATION WITH SYNTHETIC ANALOGS OF 2-LYSOPHOSPHATIDYLCHOLINE [J].
ANDREESEN, R ;
OSTERHOLZ, J ;
LUCKENBACH, GA ;
COSTABEL, U ;
SCHULZ, A ;
SPETH, V ;
MUNDER, PG ;
LOHR, GW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1984, 72 (01) :53-59
[3]  
BAUMANN WJ, 1987, LIPIDS, V22, P775
[4]  
BERDEL WE, 1990, ONKOLOGIE, V13, P245
[5]  
BERDEL WE, 1981, J NATL CANCER I, V66, P813
[6]  
BERDEL WE, 1983, CANCER RES, V43, P541
[7]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[8]  
CASTAGNA M, 1982, J BIOL CHEM, V257, P7847
[9]  
HELFMAN DM, 1983, CANCER RES, V43, P2955
[10]  
HERRMANN DBJ, 1985, J NATL CANCER I, V75, P423